New combo pills for blood pressure and diabetes pass first safety check in healthy volunteers
NCT ID NCT07598968
First seen May 31, 2026 · Last updated Jun 22, 2026 · Updated 2 times
Summary
This early-stage trial tested the safety and how the body processes two experimental drugs, HL1113-R1 and HL1113-R2, in 35 healthy adults. Participants took the drugs alone and together over a few weeks. The goal was to check for side effects and measure drug levels, not to treat any disease. Results will help decide if further studies are safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Central Hospital
Seoul, South Korea
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HL1113-R1 and HL1113-R2 (oral drugs for hypertension and type 2 diabetes)
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.